A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 472-476

  Shinohara, N ^a   Nonomura, N ^b   Eto, M ^c   Kimura, G ^d   Minami, H ^e   Tokunaga, S ^f   Naito, S ^g  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e KOBE UNIVERSITY HOSPITAL   (Japan)

^f KYUSHU UNIVERSITY HOSPITAL   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

Author keywords

Ceramide; Hand foot skin reaction; Hydrocolloid dressing; Renal cell carcinoma; Sorafenib

Indexed keywords

CERAMIDE; SORAFENIB; UREA; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HAND FOOT SYNDROME; HUMAN; HYDROCOLLOID DRESSING; KIDNEY CARCINOMA; LIFE EXPECTANCY; MALE; MULTICENTER STUDY; OPEN STUDY; PAIN; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHYSICAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SOCIAL DISABILITY; THERAPY EFFECT; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; HAND-FOOT SYNDROME; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; PATHOLOGY; SECONDARY; SURFACE PROPERTY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BANDAGES, HYDROCOLLOID; CARCINOMA, RENAL CELL; CERAMIDES; FEMALE; HAND-FOOT SYNDROME; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; SURFACE PROPERTIES; TREATMENT OUTCOME;

EID: 84893399915     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt541     Document Type: Article

References (18)

1. Wada Y, Takahashi W, Kawano Y et al. Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan. Int J Urol 2012; 19: 284-295.
2. Bellmunt J, Eisen T, Fishman M et al. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011; 78: 24-32.
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
4. Akaza H, Tsukamoto T, Murai M et al. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007; 37: 755-762.
5. Edmonds K, Hull D, Spencer-Shaw A et al. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment for renal cell and hepatocellular carcinoma: Recommendations from a European nursing task group. Eur J Oncol Nurs 2012; 16: 172-184.
6. Yang C-H, Lin W-C, Chung C-K et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008; 158: 592-596.
7. Nakagami G, Sanada H, Konya C et al. Evaluation of a new pressure ulcer preventive dressing containing ceramide 2 with low frictional outer layer. J AdvNurs 2007; 59(5): 520-529.
8. Chu D, Lacouture ME, Fillos T et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008; 47: 176-186.
9. Iijima M, Fukino K, Adachi M et al. Sorafenib-associated hand-foot syndrome in Japanese patients. J Dermatol 2011; 38: 261-266.
10. Morita E, Lee DG, Sugiyama M et al. Expression of c-kit ligand in human keratinocytes. Arch Dermatol Res 1994; 286: 273-277.
11. Azad NS, Aragon-Ching JB, Dahut WL et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 1411-1416.
12. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmer-planter erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009; 77: 257-271.
13. Daniel RK, Priest DL, Wheatley DC. Etiologic factors in pressure sores: an experimental model. Arch Phys Med Rehabil 1981; 62: 492-498.
14. Lacouture ME, Reilly LM, Gerami P et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 2008; 19: 1955-1961.
15. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001-1011.
16. Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J Support Oncol 2011; 9: 13-23.
17. Balagula Y, Wu S, Su X et al. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2012; 30: 1773-1781.
18. Lee JH, Chung Y-H, Kim JA et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 2013; 119: 136-142.